XML 53 R22.htm IDEA: XBRL DOCUMENT v3.22.4
Share-based Compensation
12 Months Ended
Dec. 31, 2022
Share-based Payment Arrangement [Abstract]  
Share-based Compensation
Share-based Compensation
The Company maintains a share-based compensation plan, which authorizes the granting of various equity-based incentives including stock options and RSUs to employees and nonemployee directors. The number of shares of common stock reserved for issuance under the plan was 34.4 million at December 31, 2022, including 21.8 million available for future grants.
Share-based compensation expense and the effect on diluted earnings per common share were as follows:
In millions, except per share data202220212020
Share-based compensation expense$166.7 $139.2 $92.4 
After tax$145.9 $120.4 $78.3 
Earnings per common share-diluted$0.20 $0.16 $0.10 
As of December 31, 2022, there was $161.1 million of total unrecognized compensation cost related to nonvested share-based compensation that is expected to be recognized over a weighted-average period of 2.0 years.
STOCK OPTIONS
Stock options to purchase common stock are granted with an exercise price equal to the closing market price of the Company’s stock on the date of grant. Substantially all of the options become exercisable in four equal installments, beginning a year from the date of the grant, and generally expire 10 years from the grant date.
The following table presents the weighted-average assumptions used in the option pricing model for the 2022, 2021 and 2020 stock option grants. The expected life of the options represents the period of time the options are expected to be outstanding and is based on historical trends. Expected stock price volatility is generally based on the historical volatility of the Company’s stock for a period approximating the expected life. The expected dividend yield is based on the Company’s most recent annual dividend rate. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant with a term equal to the expected life.

Weighted-average assumptions
202220212020
Expected dividend yield2.2 %2.4 %2.3 %
Expected stock price volatility21.3 %21.8 %19.1 %
Risk-free interest rate1.9 %0.7 %1.4 %
Expected life of options (in years)
5.75.75.7
Fair value per option granted$42.12 $30.91 $29.40 

Intrinsic value for stock options is defined as the difference between the current market value of the Company’s stock and the exercise price. During 2022, 2021 and 2020, the total intrinsic value of stock options exercised was $242.2 million, $302.0 million and $290.4 million, respectively. Cash received from stock options exercised during 2022 was $248.2 million and the tax benefit realized from stock options exercised totaled $48.3 million. The Company uses treasury shares purchased under the Company’s share repurchase program to satisfy share-based exercises.
A summary of the status of the Company’s stock option grants as of December 31, 2022, 2021 and 2020, and changes during the years then ended, is presented in the following table:
202220212020
OptionsShares in
millions
Weighted-
average
exercise
price
Weighted-
average
remaining
contractual
life in years
Aggregate
intrinsic
value in
millions
Shares in
millions
Weighted-
average
exercise
price
Shares in
millions
Weighted-
average
exercise
price
Outstanding at beginning of year12.0 $156.13 13.4 $139.44 14.6 $124.21 
Granted1.6 252.97 2.1 215.73 1.8 214.18 
Exercised(1.9)128.08 (2.4)115.29 (2.8)104.58 
Forfeited/expired(0.3)225.93   (1.1)160.50 (0.2)184.69 
Outstanding at end of year11.4 $172.27 5.6$1,041.6 12.0 $156.13 13.4 $139.44 
Exercisable at end of year7.7 $145.87 4.4$904.2 7.8 8.8  
RSUs
RSUs generally vest 100% on the third anniversary of the grant and are payable in either shares of the Company’s common stock or cash, at the Company’s discretion. The fair value of each RSU granted is equal to the market price of the Company’s stock at date of grant. Separately, Company officers have been awarded RSUs that vest based on Company performance. For performance-based RSUs, the Company includes a relative TSR modifier to determine the number of shares earned at the end of the performance period. The fair value of performance-based RSUs that include the TSR modifier is determined using a Monte Carlo valuation model.
A summary of the Company’s RSU activity during the years ended December 31, 2022, 2021 and 2020 is presented in the following table:
 202220212020
RSUsShares in
millions
Weighted-
average
grant date
fair value
Shares in
millions
Weighted-
average
grant date
fair value
Shares in
millions
Weighted-
average
grant date
fair value
Nonvested at beginning of year1.3 $197.10 1.3 $176.81 1.4 $150.95 
Granted0.5 242.82 0.6 206.92 0.6 201.92 
Vested(0.4)173.31 (0.4)153.55 (0.6)127.99 
Forfeited(0.2)205.61 (0.2)168.38 (0.1)172.45 
Nonvested at end of year1.2 $222.32 1.3 $197.10 1.3 $176.81 
The total fair value of RSUs vested during 2022, 2021 and 2020 was $110.3 million, $80.0 million and $119.4 million, respectively. The tax benefit realized from RSUs vested during 2022 was $18.5 million.